Machine Learning Approach Identifies Independent Prognostic Value of Flow Cytometry (FCM) in Myelodysplastic Syndromes (MDS)
Uta Oelschlaegel(University Hospital Carl Gustav Carus), Uwe Platzbecker(National Center for Tumor Diseases), Kevin Blighe(King's College London), Susann Winter(University Hospital Carl Gustav Carus), Katja Sockel(Innsbruck Medical University), Shahram Kordasti(Guy's Hospital), Martin Bornhäuser(Technische Universität Dresden)
Cited by 1
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
|Blood|2019|655
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
|The Lancet Oncology|2015|402